Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Med Discovery S.A.
DescriptionRecombinant protease inhibitor targeting human kallikrein-related peptidase 2 (KLK2; hK2)
Molecular Target Kallikrein-related peptidase 2 (KLK2) (hK2)
Mechanism of ActionKallikrein inhibitor
Therapeutic Modality 
Latest Stage of DevelopmentPreclinical
Standard IndicationProstate cancer
Indication DetailsTreat prostate cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today